INFLUENCE OF METHOD OF PREPARATION ON SOLUBILITY, PHYSICOCHEMICAL PROPERTIES AND IN-VITRO RELEASE PROFILE OF SIMVASTATIN- CYCLODEXTRIN INCLUSION COMPLEXES: A COMPARATIVE STUDY

SHIVANAND S.SHIRALASHETTI 1, AJAYKUMAR S PATIL 1, JAGADEVAPPA S PATIL*2

1 Dept. of Pharmaceutics, Karnataka College of Pharmacy, P.B #53,Manahalli Road, Bidar - 585 403, 2Dept.of Pharmaceutics, BLDEA s College of Pharmacy, BLDE University campus, Bijapur-586 103, Karnataka, India. E-mail: Pharmajspatil@gmail.com

Received 12 Dec 2009, Revised and Accepted 01 Jan 2010

ABSTRACT

This study was performed with the intention of finding the effect of preparation methods on the solubility and dissolution of Simvastatin (SV) hydroxypropyl β-cyclodextrin (HPβ-CD) inclusion complexes. The complexes were prepared by simple Physical mixing, Kneading and Spray drying techniques. The inclusion complexes were evaluated for phase solubility and in-vitro release study. The complexes were also subjected for physicochemical characterizations. The differential scanning colorimetry (DSC) and X-ray diffractometry (XRD) results revealed that no endothermic and characteristic diffraction peaks of SV was observed in both the inclusion complexes. The study indicated the conversion crystalline form of SV into the amorphous form. Aqueous solubility and dissolution profiles of SV were markedly increased in inclusion complexes, compared with the drug alone and physical mixture. Moreover, spray dried inclusion complexes found better in all the studied parameters in comparison of the complexes prepared by other methods. The Spray drying technique for the preparation of inclusion complexes can serve as a best method for better aqueous solubility and dissolution profiles of poorly soluble drugs.

Key words: Simvastatin, HPβ-CD, Spray drying, Inclusion complex, Dissolution rate.

INTRODUCTION

Simvastatin (SV) is a lipid lowering-agent derived structurally from a fermentation product of Aspergillus terraeus1 and widely used to hypercholesterolemia and it is a potent inhibitor of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is an early rate-limiting step in the biosynthesis of cholesterol2. Therefore, it is very important to introduce effective methods to enhance the solubility and dissolution rate of drug, substantially leading to its bioavailability.

Cyclodextrins (CDs) are cyclic oligosaccharides, which are produced by enzymatic degradation and have been recognized as useful pharmaceutical excipients3. Complexation with cyclodextrins has been reported to enhance the solubility, dissolution rate and bioavailability of poorly water soluble drugs, especially, hydroxypropyl β-cyclodextrin is widely used in the pharmaceutical field owing to its high aqueous solubility and ability to stabilize the drug molecule4. The hydrophobic cavity of cyclodextrins in this way increases solubility, bioavailability and stability5. Previously, inclusion complex of SV with α-CD and β-CD was reported6 but the extensive work is needed. Here, an attempt was made to study the influence of spray drying technique on solubility, physicochemical properties and in-vitro drug release profile, the same were compared with the inclusion complexes prepared by other methods.

MATERIALS AND METHODS

Simvastatin was received as a gift sample from Lincoln pharmaceuticals Ltd, (Ahmedabad, India). HPβ-CD was a generous gift received from Gangwal chemicals Pvt. Ltd.(Mumbai, India).All Chemicals and solvents used in the study were of analytical reagent grade. Fresh distilled water was used.

Phase solubility study

50 mg SV was added to 15 ml distilled water containing 0 to 10 mM of HPβ-cyclodextrin and transferred to 25 ml stoppered conical flask. The mixture was shaken for 72hrs. Aliquots of 2 ml were withdrawn and filtered immediately using 0.45 μ nylon disc filter. The filtered samples were diluted suitably and assayed for Simvastatin by measuring absorbance at 238 nm against blank. The experiments were conducted in triplicate. The apparent solubility constant (Kc) according the hypothesis of 1:1 stoichiometric ratio of complexes was calculated from the phase-solubility diagram using the following equation.

\[ K_{ab} = \frac{\text{slope}}{S_0 (1\text{-slope})} \]

The slope is obtained from the initial straight line portion of the plot of Simvastatin against cyclodextrin concentration, and \(S_0\) is the equilibrium solubility of Simvastatin in water8.

Preparation of inclusion complexes

Physical mixture

Drug and HPβ-CD (CD) in the molar ratios of 1:1 were mixed separately in a mortar for about one hour with constant trituration, the mixture was passed through sieve # 100 and stored in the desiccators over fused calcium chloride.

Kneading method

SV with HPβ-CD in the molar ratio of 1:1 was used for preparing the inclusion complex. HPβ-CD was placed in a mortar, a small quantity of 50% methanol was added to it while triturating to get slurry like consistency. Then the drug was slowly incorporated into the slurry and trituration was further continued for one hour. Slurry was then air dried at 25°C for 24 hours, pulverized, passed through sieve # 100 and stored in desiccators over fused calcium chloride.

Spray drying method

The drug and HPβ-CD were dissolved in isopropyl alcohol (IPA) and distilled water separately with the help of a magnetic stirrer. Both the solutions were mixed slowly and drop wise together on a magnetic stirrer for 30min. The resulting solution was fed to mini spray dryer (Labultima-222,Mumbai,India) and sprayed in the chamber from a nozzle with diameter 0.7mm under the atomization pressure of 1.5kg/cm2 for 24 hours. The inlet temperature was kept at 80 °C and out let temperature 60 °C ± 2 °C. The vacuum in the system was 50mmwc and aspirator was 45%. The product thus obtained was collected, packed and doubly wrapped in a aluminum foil and stored in a desiccator till further use9.
Table 1: Compositions of formulations in molar ratios

<table>
<thead>
<tr>
<th>Method</th>
<th>Drug to carrier</th>
<th>Drug to carrier ratio</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pure drug Simvastatin</td>
<td>SV/HPβ-CD</td>
<td>1:1</td>
<td>F0</td>
</tr>
<tr>
<td>Physical Mixture (PM)</td>
<td>SV/HPβ-CD</td>
<td>1:1</td>
<td>F1</td>
</tr>
<tr>
<td>Kneading (KM)</td>
<td>SV/HPβ-CD</td>
<td>1:1</td>
<td>F2</td>
</tr>
<tr>
<td>Spray Drying (SD)</td>
<td>SV/HPβ-CD</td>
<td>1:1</td>
<td>F3</td>
</tr>
</tbody>
</table>

**EVALUATION OF INCLUSION COMPLEXES**

**Drug content**

Inclusion complexes prepared by physical mixture, kneading, and spray drying methods were assayed for drug content by dissolving a specific amount of the complexes in methanol and analyzed for the drug content spectrophotometrically at 238 nm.

**Aqueous solubility**

An excess amount of sample was added to 5 ml of the distilled water in test tubes sealed with stoppers. The test tubes were vortex-mixed for 5 min. and then sonicated for 30 min. They were kept in a constant temperature shaking bath maintained at 37 ± 0.5 °C until reaching equilibrium (48 h). A portion of the solution was withdrawn and then filtered with a nylon disc filter (0.45 µm) and adequately diluted with methanol. The amount of drug solubilised was determined at 238 nm by UV-spectrophotometer (UV-1240, Shimadzu, Japan).

**In vitro drug release rate studies**

Dissolution study of pure SV and its complexes was performed using USP dissolution apparatus type (USPXX IV). 500 ml of 1.2 pH simulated gastric fluid (SGF) and 7.4 pH Buffer solutions were used as the dissolution media. The study was conducted at 37°C±0.5°C with a rotation of 50 rpm. At fixed time intervals 5 ml aliquots were withdrawn, filtered, suitably diluted, and assayed for SV content by measuring the absorbance at 238 nm using a spectrophotometer over a period of two hours. After each sampling, the volume of the dissolution medium was replenished with equal volume of fresh medium at the same temperature to maintain its constant volume throughout the study. The studies were performed in triplicate (n=3). The mean values were calculated for cumulative drug release and the same was used while plotting the release curves. The percent drug released at various time intervals was calculated and plotted against time.

**Characterization of complexes**

- **X-ray diffraction study (XRD)**
  The XRD study was done to analyze the powder characteristics of SV and its inclusion complexes. X-ray diffractograms were obtained by Philips diffractometer (PW 1140) and Cu-Kα radiation. Diffractograms were run at a scanning speed of 2°/min and a chart speed of 2°/2 cm/2θ.

- **Differential scanning calorimetry study (DSC)**
  The DSC measurements were performed using a Perkin Elmer Pyris (Shelton, CT) and mettler equipped with an intercooler 2P cooling accessory. Samples of 4mg were placed in standard aluminum pans and sealed with a lid. Heating scans by 10°C/min were applied with a nitrogen purge of 20ml/min, over a temperature range of 30°C to 285°C. An empty aluminum pan was used as reference.

- **Scanning electron microscopy study (SEM)**
  The morphology of samples was studied using SEM (HITACHI S-3000N, Japan), operated at an accelerating voltage of 20 kV (lament current of 1.75mA beam current of 30 ~ 40 mA and probe current of 250 pA). Samples were prepared by mounting 0.5 mg of powder onto a 5mm silicon wafer a fixed via graphite tape to an aluminum stub. The powder was then sputter-coated for 40 s at beam current of 38 ~ 42 mA with a 200 A° layer of gold/palladium alloy.

- **Particle size analysis**
  The particle size analysis of both the drug and inclusion complexes was carried out using laser channel beam instrument (CIS-50, Anskermid, Netherlands). The range of particles used for scanning was 1nm -150nm. The lens used was A lens. The particles were suspended in liquid paraffin to give a concentration of 10⁶ particles/ml with a SNF value of 1. The sample prepared was placed in to the cuvets made of polystyrene of 1cm path length. The particles were analyzed for their size (length×breadth ×volume) by using laser channel beam.

![Fig 1: Phase solubility study of SV-HPβ-CD complex.](image-url)
RESULTS

Phase-solubility study

The apparent solubility constant (Kc) obtained from the slope of the linear phase solubility diagrams was found to be 727.73M⁻¹. Drug content

The percentage of drug content for all the formulations was found to be between the range of 97.5% and 99.20%.

Aqueous solubility

At the end of 48 hours aqueous solubility of SV was found to be 157μg/ml. Where as, for the physical mixture of SV-HP-βCD it was found to be 464μg/ml. In the formulations prepared by kneading method it was 501μg/ml and in spray drying method it was further enhanced to 539μg/ml (Table 2).

<table>
<thead>
<tr>
<th>Sl.no</th>
<th>Formulations</th>
<th>Aqueous solubility in μg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F0</td>
<td>157.0</td>
</tr>
<tr>
<td>3</td>
<td>F1</td>
<td>464.0</td>
</tr>
<tr>
<td>5</td>
<td>F2</td>
<td>501.0</td>
</tr>
<tr>
<td>7</td>
<td>F3</td>
<td>585.0</td>
</tr>
</tbody>
</table>

Table 2: Data of Aqueous solubility

Particle size analysis

The particle size analysis of spray dried pure drug F0 formulations F1, F2 and F3 was carried out using laser channel beam. The mean particle size of pure spray dried drug is quite bigger than the inclusion complexes prepared by different methods. However, the particle size of F1 is little greater than F2 and F3 (Table 3).

Dissolution studies

The percent drug release data from various inclusion complexes was found in the range of 58.68 to 99.60% within 120 minutes (Table 4 & 5). The pure drug exhibited only 14 to 35% of release. The drug release profile of the formulations F0, F1, F2 & F3 in pH 1.2 buffer solution was found to be 65.32%, 99.28% and 99.32% respectively, whereas in pH 7.4 buffer it was 74.82.32%, 99.56% and 99.40% respectively.

<table>
<thead>
<tr>
<th>Time in min</th>
<th>Formulation code</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td>F0</td>
</tr>
<tr>
<td>60</td>
<td>F1</td>
</tr>
<tr>
<td>90</td>
<td>F2</td>
</tr>
<tr>
<td>120</td>
<td>F3</td>
</tr>
</tbody>
</table>

Table 3: Data of Particle size analysis

Table 4: In-vitro drug release profiles in pH 1.2 Buffer

<table>
<thead>
<tr>
<th>Time in min</th>
<th>Formulation code</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td>F0</td>
</tr>
<tr>
<td>60</td>
<td>F1</td>
</tr>
<tr>
<td>90</td>
<td>F2</td>
</tr>
<tr>
<td>120</td>
<td>F3</td>
</tr>
</tbody>
</table>

Fig 2: In vitro drug release study in pH 1.2 Buffer

Table 5: In vitro drug release profiles in pH 7.4 Buffer

<table>
<thead>
<tr>
<th>Time in min</th>
<th>Formulation code</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td>F0</td>
</tr>
<tr>
<td>60</td>
<td>F1</td>
</tr>
<tr>
<td>90</td>
<td>F2</td>
</tr>
<tr>
<td>120</td>
<td>F3</td>
</tr>
</tbody>
</table>
The XRD patterns of pure drug (SV), HPβ-CD and SV: HPβ-CD systems are represented in figure 4. The diffractograms of SV and HPβ-CD exhibited a series of intense peaks, which is an indicative of their crystalline nature. XRD pattern of physical mixture (F1) is simply the superimposition of each component indicating no formation of new structure. Complex prepared by kneading method (F2) showed a diffraction pattern quite similar to that of physical
mixture, while those obtained from Spray drying method (F3) showed less peaks with low intensity.

Differential scanning calorimetry (DSC)

The DSC thermo grams of pure SV and HPβ-CD and corresponding inclusion complexes are presented in figure 5. SV was characterized by a single, sharp melting endotherm at 139.5°C DSC analysis and the thermogram of HPβ-CD showed a very broad endothermic effect, which attained a maximum around 70°C and 100°C, respectively, due to the release of water molecules. The thermo grams of inclusion complexes prepared by physical mixture (F1) and kneading method (F2) respectively showed endothermic peaks at 68.4°C and 102-79°C. The spray dried complex (F3) showed complete disappearance of peak.

**Fig 6:** DSC thermograms of HPβ-CD, SV, F1 (PM SV/HPβ-CD), F2 (KN SV/HPβ-CD) and F3 (SD SV/HPβ-CD) the inclusion complexes

Scanning electron microscopy (SEM)

SEM is used to assess the microscopic surface morphology of the drug and complexes. Pure drug is characterized by the presence of crystalline particle of a regular size. The physical mixture (F1) showed slight crystalline structure of both drug and complexing agents. Crystals of drug mixed with crystals of complexing agents were seen adhering to the surface. The SEM photographs of inclusion complexes prepared by kneading method (F2) seen to be slightly amorphous structure for both drug and complexing agents. The photographs of spray dried inclusion complexes (F3) showed the characteristic morphology as a small sized particles tending to aggregation, indicating the existence of an amorphous product with presence of single component in the complex thus suggesting maximum complexation.
DISCUSSION

The inclusion complexes prepared by different methods were evaluated and characterized by various measures. The phase-solubility diagram of SV in various concentrations of HPβ-CD was linear and the type of complex is classified as A₁ type. The aqueous solubility of SV was increased linearly as a function of the concentration of HPβ-CD with a slope of <1 showing that the increase in the solubility was due to the formation of 1:1 M complex. The stability constant (Kc) value obtained was indicated that the complexes formed were quite stable in the above-said molar ratio. The results of solubility study revealed that there was a great improvement in the dissolution profile is mainly due to the better enhancement in the aqueous solubility of complex prepared by spray drying method when compared to other methods. This may be due to the uniform particle size in the spray dried complex. As per the results of particle size analysis the inclusion complex prepared by spray dried method showed smaller particles compared to the complexes prepared by other methods. This may be due to the uniform droplets obtained in the spray drying process. The marked improvement in dissolution rate of SV was observed inclusion complexes prepared by kneading and spray drying method. This improvement in dissolution profile is mainly due to the better interaction of drug and cyclodextrin taking place by these preparation techniques.

The XRD analysis indicates that the inclusion complex prepared by a spray drying method showed conversion of drug crystallinity into amorphous state in its complex form. But this did not achieved in complexes prepared by physical mixture and kneading method. This was further confirmed by DSC thermograms. The DSC analysis of the formulations suggests that the complete interaction of drug and complexing agent at the molecular level is achieved by spray drying combination technique. The SEM of SV, SV/HPβ-CD (PM), SV/HPβ-CD KN- complex and SV/HPβ-CD SD-complex is shown in figure 7. SEM of SV showing large crystals. SV/HPβ-CD (PM), SV/HPβ-CD KN- complex has appeared as irregular-shaped crystals. In contrast, a drastic change in the morphology and shape of drug was observed in the SV/HPβ-CD SD-complex, revealing an apparent interaction, in the solid state.

CONCLUSION

Since, from the results of the study it can be concluded that the method of inclusion complex preparation has considerable influence on dissolution rate and solubility of simvastatin. Spray drying technique is used in the preparation of inclusion complex as shown considerably better results in comparison of kneading and physical mixture methods. So, it may be feasible to prepare past dissolving tablets of simvastatin by suitable spray dried inclusion complex.

REFERENCES


Fig 7: SEM photographs of SV, F₁ (PM SV/HPβ-CD), F₂ (KN SV/HPβ-CD) and F₃ (SD SV/HPβ-CD) the inclusion complexes